Updates in Drug Treatment of Severe Hypertriglyceridemia.

ABSTRACT:

Purpose of review

To provide an insight into the new pharmacological options for the treatment of severe hypertriglyceridemia (sHTG).

Recent findings

sHTG is difficult to treat. The majority of the traditional pharmacological agents available have limited success in both robustly decreasing triglyceride levels and/or in reducing the incidence of acute pancreatitis (AP), the most severe complication of sHTG. Therapeutic options with novel mechanisms of action have been developed, such as antisense oligonucleotides (ASO) and small interfering RNA (siRNA) targeting APOC3 and ANGPTL3. The review discusses also 2 abandoned drugs for sHTG treatment, evinacumab and vupanorsen. The ASO targeting APOC3, volanesorsen, is approved for use in patients with familial chylomicronemia syndr

SUBMITTER: Gouni-Berthold I 

PROVIDER: S-EPMC10564803 | biostudies-literature | 2023 Oct

REPOSITORIES: biostudies-literature